United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Pfizer (PFE) Recently Broke Out Above the 200-Day Moving Average

British American Tobacco

Kinder Morgan

Realty Income Corp

Simon Property Group

Neos S&P 500 High Income ETF

The stock market closed at record highs in the third week of May, with the S&P 500 exceeding 40,000. The Dividend Harvesting Portfolio reached another all-time high, with an ROI of 14.44% and a forward projected dividend income of $1,496.16. The portfolio is diversified across various asset classes, with equities, ETFs, REITs, CEFs, and BDCs generating significant dividend income.

Dividend Harvesting Portfolio Week 168: $16,800 Allocated, $1,496.16 In Projected Dividends

Best Buy

Kohl's

Lincoln National

Whirlpool

Investors looking to generate passive income need to consider stocks that while well-known often get overlooked in the discussion for  the top dividend ideas.

Don't Forget These 5 Passive Income Dividend Stocks With Yields as High as 8.4%

Pfizer is also carrying out another $4 billion cost-cutting effort, which it announced last year as demand for its Covid vaccine and drug Paxlovid slumped.

Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts

The company said it estimates savings of $1.5 billion in the plan's first phase by the end of 2027.

Pfizer to Cut Costs in Multi-Year Effort

U.S. drugmaker Pfizer said on Wednesday it had launched a multi-year program to reduce expenses and aims to save about $1.5 billion in costs by the end of 2027.

Pfizer launches multi-year cost-cuts program, eyes $1.5 bln in savings

Kenvue

Medtronic

It's a great time to be looking at healthcare stocks to buy now. According to research from BlackRock, U.S. healthcare stocks have outperformed the overall stock market by an average of 10% over the past seven recessions.

3 Healthcare Stocks to Buy Now: May 2024

TEDA TIANJIN, China--(BUSINESS WIRE)--Asymchem establishes their first manufacturing facility in Europe with the acquisition of a former Pfizer small molecule API pilot plant in Sandwich.

Asymchem Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities

Caterpillar

Hershey

Despite a recent slowdown, the future of the U.S. economy appears promising. Economists remain optimistic, citing resilient consumer activity as a driving force for continued growth.

3 Blue-Chip Stocks to Buy on the Dip: May 2024

JPMorgan Equity Premium Income ETF

Schwab US Dividend Equity ETF

Retirement investing can be challenging due to diverse needs and unique financial situations. Inflation reduces purchasing power and higher withdrawal rates impact net worth, making high-quality income stocks important. I highlight two ETFs and three dividend (growth) stocks that provide a great blend of income and growth at very attractive prices.

Up To 7% Yield - 5 Attractive High-Yield Picks To Help You Retire (Early)

Pfizer stock has fallen by about half from the peak it reached about two years ago. Some billionaire fund managers placed big bets on Pfizer in the first quarter.

Billionaires Are Buying Beaten-Down Pfizer Stock Hand Over Fist. Should You Follow Their Lead?

Walgreens

Dividend-paying stocks have more than doubled up the annualized average return of non-payers over the last half-century. Although roughly 80% of S&P 500 companies pay a regular dividend, only a little over a dozen sport a truly supercharged yield.

Time to Pounce: 2 Ultra-High-Yield S&P 500 Dividend Stocks That Are Screaming Buys Right Now

Comcast

Investors should have a wide range of companies in multiple sectors within their investment portfolio. But the backbone of any resilient portfolio that can withstand a bear market and soar during a bull market are blue-chip stocks.

3 Blue-Chip Stocks Set to Triple Soon

Crown Castle International

Enterprise Products Partners

Altria

Verizon

Smart Investors Are Quietly Loading Up on These “Dividend Legends” If you want your portfolio to pay you cash like clockwork, it's time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

6 Safe Blue Chip Dividend Stocks That Yield More Than Treasury Bonds

These three stocks offer yields ranging from 5.8% to 7.2%. All three are attractively valued with relatively low forward earnings multiples.

3 High-Yield Dividend Stocks I'm Buying Hand Over Fist

Realty Income is one of the largest real estate investment trusts you can invest in. Combustible tobacco sales are sinking for Altria Group, but it could transition heaps of customers to its new e-vapor products.

3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With Less Than $100 Right Now

Billionaire money managers bought millions of shares of high-yield healthcare stocks during the first three months of 2024. John Overdeck and David Siegel of Two Sigma Investments bought over 8 million Pfizer shares, and they weren't the only billionaires interested in the pharmaceutical giant.

Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?

AstraZeneca

AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.

Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial

Pfizer's earnings and sales have fallen due to decreased demand for COVID-19-related products, leading to a large selling pressure this year. The stock price has recently started rebounding from its low point and is showing bullish technical signs for continued momentum. Besides these technical signs, I also see fundamental catalysts that could support further price rallies.

Pfizer Stock: Rebound Has Started (Technical Analysis)

AbbVie

Boeing

CVS Health

Johnson & Johnson

Lockheed Martin

Procter & Gamble

Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.

7 Value Stocks to Buy and Hold for a Decade of Dominance

Pfizer's stock has struggled to recover since the pandemic, but its high dividend yield of 5.9% makes it an attractive option for income investors. The company faces risks from upcoming patent expiries and the impact of rising interest rates on its debt and ability to invest in research and development. Despite these challenges, Pfizer's valuation metrics suggest it is attractively priced, and a dividend discount model estimates a potential upside of over 30% from the current price level.

Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield

Teladoc

While healthcare is broadly resilient in times of economic stress, each company needs its own evaluation. Pfizer is dealing with a period of transition, but its business has only been bolstered by pandemic successes.

2 Top Growth Stocks Down 24% and 50% to Buy With $100

Coca-Cola

Starbucks

The combination of earnings season and a dovish Fed are pushing the markets closer to all-time highs. The Dividend Harvesting Portfolio has reached an all-time high in profitability and account value, with a 13.14% return on invested capital. The portfolio is generating $1,495.50 in forward dividend income, with equities, ETFs, REITs, CEFs, and BDCs contributing to the dividend income.

News for Pfizer Stock (PFE)